Adicet Bio (ACET) to Announce Earnings on Thursday

Adicet Bio (NASDAQ:ACET) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($1.6920) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Adicet Bio (NASDAQ:ACET) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($1.88) EPS for the quarter, topping the consensus estimate of ($2.93) by $1.05. On average, analysts expect Adicet Bio to post $-9 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Adicet Bio Stock Performance

NASDAQ:ACET opened at $8.25 on Thursday. The company has a quick ratio of 7.65, a current ratio of 7.66 and a debt-to-equity ratio of 0.01. Adicet Bio has a twelve month low of $6.01 and a twelve month high of $17.44. The company has a fifty day moving average of $8.28 and a 200-day moving average of $7.78. The firm has a market capitalization of $77.17 million, a P/E ratio of -0.55 and a beta of 1.58.

Analysts Set New Price Targets

ACET has been the subject of a number of research reports. Jefferies Financial Group started coverage on shares of Adicet Bio in a report on Tuesday, May 5th. They issued a “buy” rating and a $19.00 price target for the company. Wall Street Zen upgraded shares of Adicet Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings raised shares of Adicet Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.80.

Hedge Funds Weigh In On Adicet Bio

A number of large investors have recently modified their holdings of the company. Susquehanna International Group LLP bought a new stake in Adicet Bio during the 3rd quarter valued at $33,000. Squarepoint Ops LLC acquired a new position in shares of Adicet Bio during the third quarter valued at about $38,000. Virtu Financial LLC bought a new stake in shares of Adicet Bio during the third quarter worth about $65,000. Citadel Advisors LLC raised its holdings in shares of Adicet Bio by 19.8% in the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock worth $473,000 after acquiring an additional 96,342 shares during the last quarter. Finally, Luminus Management LLC acquired a new stake in shares of Adicet Bio in the 4th quarter worth about $501,000. 83.89% of the stock is currently owned by institutional investors.

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.